Integrated Solubility Enhancement and Tablet Formulation of Lercanidipine Hydrochloride Using Design of Experiments
International Journal of Drug Delivery Technology · 21.01.2026 · 16 (01)
DOI: 10.25258/ijddt.16.1.36 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 21.01.2026. Verfasst von Sanyasi Swain und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Lercanidipine hydrochloride (HCl) is a poorly soluble calcium channel blocker limiting its oral bioavailability and therapeutic efficacy. Increasing its dissolution rate through appropriate formulation methods is essential for improved clinical outcomes. Methodology: Solid dispersions of lercanidipine HCl were developed using hydrophilic carriers poloxamer 188, polyethylene glycol 6000, and polyvinylpyrrolidone K30 by solvent evaporation and fusion techniques at different drugto-carrier ratios. Dispersible tablets were formulated from these solid dispersions, and optimization was performed using a 23 factorial design under Quality by Design principles. Characterization was conducted using FTIR, DSC, XRD, and dissolution studies, along with evaluation of tablet physical parameters such as content uniformity, hardness, friability, and disintegration time.
Results
Solid state analyses confirmed successful drug incorporation into carriers without significant interaction or loss of stability. Among formulations, poloxamer 188 (1:1 ratio) yielded the highest drug dissolution rate. The optimized tablet exhibited 99.98 % drug release within 45 min, fast disintegration (1-2 min), and satisfactory mechanical strength. Statistical analysis (ANOVA, p = 0.0113) indicated sodium starch glycolate and sodium lauryl sulfate as key variables influencing outcomes.
Conclusions
Solid dispersion strategies and factorial design optimization markedly improved the dissolution and disintegration properties of lercanidipine HCl tablets. These findings suggest practical approaches for formulation of fastdissolving oral lercanidipine preparations that can enhance patient benefit and pharmaceutical quality.
Zitieren
APA
Swain, S., Mahapatra, A. K., Sahu, A., & Panigrahi, R. (2026). Integrated Solubility Enhancement and Tablet Formulation of Lercanidipine Hydrochloride Using Design of Experiments. International Journal of Drug Delivery Technology, 16(01). https://doi.org/10.25258/ijddt.16.1.36
Vancouver
Swain S, Mahapatra AK, Sahu A, Panigrahi R. Integrated Solubility Enhancement and Tablet Formulation of Lercanidipine Hydrochloride Using Design of Experiments. International Journal of Drug Delivery Technology. 2026;16(01). doi:10.25258/ijddt.16.1.36
BibTeX
@article{Swain2026,
author = {Swain, Sanyasi and Mahapatra, Anjan Kumar and Sahu, Asish and Panigrahi, Rajeshree},
title = {Integrated Solubility Enhancement and Tablet Formulation of Lercanidipine Hydrochloride Using Design of Experiments},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {01},
doi = {10.25258/ijddt.16.1.36}
}
EUVIMED